drugset / Trial / NCT03361319
Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma
Phase 1/2
Withdrawn
Royal Marsden NHS Foundation Trust
Boehringer Ingelheim · collabCelgene Corporation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA
Timeline
- Start
- 2020-07
- Primary completion
- 2023-07
- Completion
- 2023-07
Outcome
Outcome not reported
Stopped (Business): “Withdrawal of financial support from funder”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 100 mg | Oral |
| Subject | Nintedanib | Small molecule | 150 mg | Oral |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |
| Background | Abraxane | Small molecule | 100 mg/m2 | — |